Clinical Trial Update: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing FS-1502 to T-DM1 for HER2-positive unresectable locally advanced or metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• FS-1502
• T-DM1 (ado-trastuzumab emtansine)

Snippet

Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN